Steven Yaplee, MD
Ophthalmology · Bakersfield, CANPI 1760678643
Payments from drug & device makers
Across 459 payments — averaging $24.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$1K
- Nova Eye, Inc.$996
- Ivantis, Inc$951
- Sight Sciences, Inc.$938
- Notal Vision, Inc.$638
- plus $4K from 30 others
What the payments were for
- Speaking & faculty fees$6386%
- Food & beverage$10,04590%
- Education$470%
- Gifts$1201%
- Other$3003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 89 | $1,881 |
| Alcon | 65 | $1,252 |
| Nova Eye, Inc. | 3 | $996 |
| Ivantis, Inc | 19 | $951 |
| Sight Sciences, Inc. | 63 | $938 |
| Notal Vision, Inc. | 2 | $638 |
| Aerie Pharmaceuticals, Inc. | 75 | $630 |
| Ocular Therapeutix, Inc. | 14 | $458 |
| Glaukos Corporation | 9 | $398 |
| Novartis | 15 | $322 |
| Sun Pharmaceutical Industries Inc. | 14 | $317 |
| Amgen(2 entities) | 16 | $310 |
| Bausch & Lomb Americas Inc. | 16 | $308 |
| Maculogix, Inc. | 2 | $155 |
| NEW World Medical,inc. | 5 | $151 |
| Dompe US, Inc. | 5 | $150 |
| Rxsight Inc | 2 | $139 |
| Rayner Intraocular Lenses Limited | 6 | $121 |
| Harrow Eye, LLC | 5 | $111 |
| Genentech USA, Inc. | 3 | $93 |
| Galderma Laboratories, L.p. | 1 | $89 |
| Apellis Pharmaceuticals, Inc. | 1 | $83 |
| Eyepoint US, Inc. | 3 | $75 |
| Biotissue Holdings Inc. | 4 | $75 |
| Iridex Corporation | 1 | $72 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $59 |
| Oyster Point Pharma, Inc. | 2 | $51 |
| Optos, Inc. | 3 | $49 |
| Revance Therapeutics, Inc. | 2 | $46 |
| Shire North American Group Inc | 2 | $45 |
| Kala Pharmaceuticals, Inc. | 2 | $45 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Mallinckrodt Hospital Products Inc. | 2 | $36 |
| Carl Zeiss Meditec, Inc. | 1 | $30 |
| Astellas Pharma US Inc | 1 | $28 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$680
- XEN GLAUCOMA TREATMENT SYSTEM$239
- AdaptDx$153
- OMNI(R) SURGICAL SYSTEM (US)$132
- Hydrus$117
- OMNI$117
- Rhopressa$115
- Rocklatan$115
- RXSIGHT CONTACT LENS$110
- RXSIGHT INJECTOR CARTRIDGE$110
- RXSIGHT INJECTOR HANDPIECE$110
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$110
- LIGHT ADJUSTABLE LENS (LAL)$110
- iStent Trabecular Micro-Bypass Stent System$109
- iStent inject Trabecular Micro-Bypass Stent System$109
How this compares
$11,149 in reported general payments places this provider in the 80th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 12 | $337,781 |
| LumiganBimatoprost | 464 | $202,554 |
| RestasisCyclosporine | 113 | $127,802 |
| Cyclosporine | 142 | $59,484 |
| CombiganBrimonidine Tartrate/Timolol | 125 | $33,048 |
| Alphagan PBrimonidine Tartrate | 103 | $31,524 |
| MieboPerfluorohexyloctane/Pf | 40 | $29,253 |
| Prednisolone Acetate | 684 | $23,685 |
| VyzultaLatanoprostene Bunod | 51 | $22,937 |
| RhopressaNetarsudil Mesylate | 58 | $21,686 |
| Brimonidine Tartrate | 145 | $20,294 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $15,985 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 78 | $13,256 |
| Ketorolac Tromethamine | 412 | $6,967 |
| Ciprofloxacin Hcl | 375 | $5,012 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,881 | $394,928805 claims |
| Dompe US, Inc.Oxervate | $150 | $337,78112 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $308 | $52,19091 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $630 | $37,67191 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Bakersfield
- Daniel ChangBakersfield$3.5M
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.